Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...
A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the ...
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Health and Me on MSN4h
GLP-1 Drugs Affect 175 Health Conditions, Benefits Heart But Pose Risk To KidneysA new study has examined the effects of GLP-1 drugs on 175 different health outcomes. ​​​While these drugs have been found to ...
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...
Robert F. Kennedy Jr., President Trump’s nominee for Health and Human Services secretary, sat through his second Senate ...
The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback